Literature DB >> 26324261

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent.

James E Ross1, Robert K Flamm2, Ronald N Jones2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26324261      PMCID： PMC4604388          DOI： 10.1128/AAC.01690-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

Review 1.  Serious infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Helen Boucher; Loren G Miller; Raymund R Razonable
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

2.  In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  James A Karlowsky; Nancy M Laing; Trish Baudry; Nachum Kaplan; David Vaughan; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing.

Authors:  John Turnidge; Gerry Bordash
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

Review 4.  New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance.

Authors:  Ian M Gould; Michael Z David; Silvano Esposito; Javier Garau; Gerard Lina; Teresita Mazzei; Georg Peters
Journal:  Int J Antimicrob Agents       Date:  2011-12-21       Impact factor: 5.283

5.  Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Authors:  Robert K Flamm; Paul R Rhomberg; Nachum Kaplan; Ronald N Jones; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

6.  AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.

Authors:  James A Karlowsky; Nachum Kaplan; Barry Hafkin; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

7.  Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.

Authors:  Nachum Kaplan; Monique Albert; Donald Awrey; Elias Bardouniotis; Judd Berman; Teresa Clarke; Mandy Dorsey; Barry Hafkin; Jaillal Ramnauth; Vladimir Romanov; Molly B Schmid; Rosanne Thalakada; Jeremy Yethon; Henry W Pauls
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

8.  In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.

Authors:  Nachum Kaplan; Donald Awrey; Elias Bardouniotis; Judd Berman; Jeremy Yethon; Henry W Pauls; Barry Hafkin
Journal:  J Chemother       Date:  2013-02       Impact factor: 1.714
  8 in total
  1 in total

Review 1.  Methods Used for the Eradication of Staphylococcal Biofilms.

Authors:  Maciej Jaśkiewicz; Adriana Janczura; Joanna Nowicka; Wojciech Kamysz
Journal:  Antibiotics (Basel)       Date:  2019-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.